ACTIONABILITY KNOWLEDGE REPOSITORY ACTIONABILITY CURATION INTERFACE
Update History
Condition: Multiple Endocrine Neoplasia Type I
Gene/Gene Panel: MEN1
Context: Adult
Date
Status
Release
Outcomes-Interventions
Notes
2022/02/09
Released
2.2.4
A
Morbidity from other MEN1-related tumors (GroupA)
Biochemical surveillance (GroupA) 10CB
Imaging surveillance (GroupA) 11CB
Morbidity from parathyroid adenoma (GroupA)
Biochemical surveillance to guide parathyroidectomy decision (GroupA) 11CB
Internal system migration associated with MONDO name addition.
Assertions
Gene Condition Pairs
Suggested Assertion
Final Assertion
MEN1 ⇔ 0007540 MULTIPLE ENDOCRINE NEOPLASIA, TYPE I; MEN1
Strong Actionability
Strong Actionability
2022/02/09
Released (Under revision)
2.2.3
A
Morbidity from other MEN1-related tumors (GroupA)
Biochemical surveillance (GroupA) 10CB
Imaging surveillance (GroupA) 11CB
Morbidity from parathyroid adenoma (GroupA)
Biochemical surveillance to guide parathyroidectomy decision (GroupA) 11CB
Assertions
Gene Condition Pairs
Suggested Assertion
Final Assertion
MEN1 ⇔ 0007540 MULTIPLE ENDOCRINE NEOPLASIA, TYPE I; MEN1
Strong Actionability
Strong Actionability
2021/10/04
Released
2.2.3
A
Morbidity from other MEN1-related tumors (GroupA)
Biochemical surveillance (GroupA) 10CB
Imaging surveillance (GroupA) 11CB
Morbidity from parathyroid adenoma (GroupA)
Biochemical surveillance to guide parathyroidectomy decision (GroupA) 11CB
Assertions
Gene Condition Pairs
Suggested Assertion
Final Assertion
MEN1 ⇔ 0007540 MULTIPLE ENDOCRINE NEOPLASIA, TYPE I; MEN1
Strong Actionability
Strong Actionability
2021/06/29
Released (Under revision)
2.2.2
A
Morbidity from other MEN1-related tumors (GroupA)
Biochemical surveillance (GroupA) 10CB
Imaging surveillance (GroupA) 11CB
Morbidity from parathyroid adenoma (GroupA)
Biochemical surveillance to guide parathyroidectomy decision (GroupA) 11CB
Corrected MONDO ID to the correct format
2020/05/12
Released
2.2.2
A
Morbidity from other MEN1-related tumors (GroupA)
Biochemical surveillance (GroupA) 10CB
Imaging surveillance (GroupA) 11CB
Morbidity from parathyroid adenoma (GroupA)
Biochemical surveillance to guide parathyroidectomy decision (GroupA) 11CB
Corrected MONDO ID to the correct format
2020/05/12
Released (Under revision)
2.2.1
A
Morbidity from other MEN1-related tumors (GroupA)
Biochemical surveillance (GroupA) 10CB
Imaging surveillance (GroupA) 11CB
Morbidity from parathyroid adenoma (GroupA)
Biochemical surveillance to guide parathyroidectomy decision (GroupA) 11CB
2020/04/22
Released
2.2.1
A
Morbidity from other MEN1-related tumors (GroupA)
Biochemical surveillance (GroupA) 10CB
Imaging surveillance (GroupA) 11CB
Morbidity from parathyroid adenoma (GroupA)
Biochemical surveillance to guide parathyroidectomy decision (GroupA) 11CB
2020/04/22
Released (Under revision)
2.2.0
A
Morbidity from other MEN1-related tumors (GroupA)
Biochemical surveillance (GroupA) 10CB
Imaging surveillance (GroupA) 11CB
Morbidity from parathyroid adenoma (GroupA)
Biochemical surveillance to guide parathyroidectomy decision (GroupA) 11CB
Internal system migration associated with Gene-Disease scoring groups upgrades.
2019/10/03
Released
2.2.0
A
Morbidity from other MEN1-related tumors (GroupA)
Biochemical surveillance (GroupA) 10CB
Imaging surveillance (GroupA) 11CB
Morbidity from parathyroid adenoma (GroupA)
Biochemical surveillance to guide parathyroidectomy decision (GroupA) 11CB
Internal system migration associated with Gene-Disease scoring groups upgrades.
2019/05/20
Released
2.1.0
A
Morbidity from other MEN1-related tumors
Biochemical surveillance 10CB
Imaging surveillance 11CB
Morbidity from parathyroid adenoma
Biochemical surveillance to guide parathyroidectomy decision 11CB
2019/05/20
Released (Under revision)
2.0.2
A
Morbidity from other MEN1-related tumors
Biochemical surveillance 10CB
Imaging surveillance 11CB
Morbidity from parathyroid adenoma
Biochemical surveillance to guide parathyroidectomy decision 11CB
2019/05/14
Released
2.0.2
A
Morbidity from other MEN1-related tumors
Biochemical surveillance 10CB
Imaging surveillance 11CB
Morbidity from parathyroid adenoma
Biochemical surveillance to guide parathyroidectomy decision 11CB
2019/05/09
Released (Under revision)
2.0.1
A
Morbidity from other MEN1-related tumors
Biochemical surveillance 10CB
Imaging surveillance 11CB
Morbidity from parathyroid adenoma
Biochemical surveillance to guide parathyroidectomy decision 11CB
2019/05/09
Released
2.0.1
A
Morbidity from other MEN1-related tumors
Biochemical surveillance 10CB
Imaging surveillance 11CB
Morbidity from parathyroid adenoma
Biochemical surveillance to guide parathyroidectomy decision 11CB
2019/05/01
Released (Under revision)
2.0.0
A
Morbidity from other MEN1-related tumors
Biochemical surveillance 10CB
Imaging surveillance 11CB
Morbidity from parathyroid adenoma
Biochemical surveillance to guide parathyroidectomy decision 11CB
2019/04/30
Released
2.0.0
A
Morbidity from other MEN1-related tumors
Biochemical surveillance 10CB
Imaging surveillance 11CB
Morbidity from parathyroid adenoma
Biochemical surveillance to guide parathyroidectomy decision 11CB
2019/04/09
Released (Under revision)
1.1.0
A
Morbidity from other neuroendocrine tumors
Biochemical surveillance 10CB
Imaging surveillance 9CB
Morbidity from parathyroid adenoma
Biochemical surveillance 10CB
Internal system migration related to merging adult and pediatric contexts.
2019/04/04
Released
1.1.0
A
Morbidity from other neuroendocrine tumors
Biochemical surveillance 10CB
Imaging surveillance 9CB
Morbidity from parathyroid adenoma
Biochemical surveillance 10CB
Internal system migration related to merging adult and pediatric contexts.
2018/11/01
Released
1.0.2
A
Morbidity from other neuroendocrine tumors
Biochemical surveillance 10CB
Imaging surveillance 9CB
Morbidity from parathyroid adenoma
Biochemical surveillance 10CB
Internal system migration related to score text replacement from E to N
2018/01/11
Released
1.0.1
A
Morbidity from other neuroendocrine tumors
Biochemical surveillance 10CB
Imaging surveillance 9CB
Morbidity from parathyroid adenoma
Biochemical surveillance 10CB
2017/10/26
Released
1.0.0
A
Morbidity from other neuroendocrine tumors
Biochemical surveillance 10CB
Imaging surveillance 9CB
Morbidity from parathyroid adenoma
Biochemical surveillance 10CB
¤ Powered by BCM's Genboree.